Imago Raises $80m Series C To Take Bomedemstat Into Phase III

Company Plans IPO In 2021 To Fund Additional Pivotal Trials

The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.

Venture Capital Concept on the Mechanism of Metal Gears.
Imago closed an $80m series C with plans to launch an IPO in 2021 • Source: Shutterstock

Imago BioSciences, Inc. revealed on 19 November that it raised $80m in series C venture capital to fund the first Phase III clinical trial for its lysine-specific demethylase 1 (LSD1 or KDM1A) inhibitor bomedemstat. The company plans to initiate additional Phase III trials in two other indications, but those will have to be funded by an initial public offering, which CEO Hugh Rienhoff said Imago expects to launch in 2021.

Bomedemstat is being studied now in ongoing Phase IIb myelofibrosis (MF) and essential thrombocythemia (ET) trials and in a Phase...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.